Rethinking anti-cancer drug discovery: the evolution from polypharmacy to unified drug units

References

1. 1.↵
   2. Naeem A,
   3. Hu P,
   4. Yang M,
   5. Zhang J,
   6. Liu Y,
   7. Zhu W, et al.

   Natural products as anticancer agents: current status and future perspectives. Molecules. 2022; 27: 8367.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Biemar F,
   3. Foti M.

   Global progress against cancer—challenges and opportunities. Cancer Biol Med. 2013; 10: 183–6.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   2. Abdin A,
   3. Schulz M,
   4. Riemer U,
   5. Hadëri B,
   6. Wachter R,
   7. Laufs U, et al.

   Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials. ESC Heart Fail. 2022; 9: 3737–50.

   OpenUrlPubMed
4. 4.↵
   2. Amani B,
   3. Amani B.

   Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis. J Med Virol. 2023; 95: e28441.
5. 5.↵
   2. Campoli-Richards DM,
   3. Brogden RN.

   Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs. 1987; 33: 577–609.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   2. Müller T.

   Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2020; 16: 403–14.

   OpenUrlPubMed
7. 7.↵
   2. Gao Q,
   3. Sheng Q,
   4. Yang Z,
   5. Zhu Z,
   6. Li L,
   7. Xu L, et al.

   Honokiol-magnolol-baicalin possesses synergistic anticancer potential and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer by triggering GSDME-dependent pyroptosis. Adv Sci (Weinh). 2025; 12: e2417022.
8. 8.↵
   2. Schlam I,
   3. Moges R,
   4. Morganti S,
   5. Tolaney SM,
   6. Tarantino P.

   Next-generation antibody-drug conjugates for breast cancer: moving beyond HER2 and TROP2. Crit Rev Oncol Hematol. 2023; 190: 104090.
9. 9.↵
   2. Bartlett NL,
   3. Hahn U,
   4. Kim W-S,
   5. Fleury I,
   6. Laribi K,
   7. Bergua J-M, et al.

   Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol. 2025; 43: 1061–72.

   OpenUrlPubMed
10. 10.↵
    2. Guo X,
    3. Luo W,
    4. Wu L,
    5. Zhang L,
    6. Chen Y,
    7. Li T, et al.

    Natural products from herbal medicine self-assemble into advanced bioactive materials. Adv Sci (Weinh). 2024; 11: e2403388.
11. 11.↵
    2. Chen Y,
    3. Jiang Y,
    4. Qu J,
    5. Wang Q,
    6. Bai Y,
    7. Shi J, et al.

    Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients. Eur J Pharm Sci. 2020; 151: 105384.
12. 12.↵
    2. Wang L,
    3. Zhou GB,
    4. Liu P,
    5. Song JH,
    6. Liang Y,
    7. Yan XJ, et al.

    Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A. 2008; 105: 4826–31.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    2. Jolivet L,
    3. Ait Mohamed Amar I,
    4. Horiot C,
    5. Boursin F,
    6. Colas C,
    7. Letast S, et al.

    Intra-domain cysteines (IDC), a new strategy for the development of original antibody fragment-drug conjugates (FDCS). Pharmaceutics. 2022; 14: 1524.

    OpenUrlPubMed
14. 14.↵
    2. Su P-L,
    3. Chakravarthy K,
    4. Furuya N,
    5. Brownstein J,
    6. Yu J,
    7. Long M, et al.

    DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. Mol Cancer. 2024; 23: 97.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Sun Y,
    3. Sha Y,
    4. Cui G,
    5. Meng F,
    6. Zhong Z.

    Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy. Adv Drug Deliv Rev. 2023; 192: 114624.
16. 16.↵
    2. Sui X,
    3. Niu X,
    4. Zhou X,
    5. Gao Y.

    Peptide drugs: a new direction in cancer immunotherapy. Cancer Biol Med. 2023; 21: 198–203.

    OpenUrlPubMed
17. 17.↵
    2. Zhang H,
    3. Liu S,
    4. Ge C,
    5. Liu X,
    6. Liu Y,
    7. Yin C, et al.

    Single-arm trials for domestic oncology drug approvals in China. Cancer Biol Med. 2023; 20: 799–805.

    OpenUrlFREE Full Text
18. 18.↵
    2. She S,
    3. Chen H,
    4. Ji W,
    5. Sun M,
    6. Cheng J,
    7. Rui M, et al.

    Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies. Front Pharmacol. 2022; 13: 1032875.
19. 19.↵
    2. Jiang XY,
    3. Shi LP,
    4. Zhu JL,
    5. Bai RR,
    6. Xie T.

    Elemene antitumor drugs development based on “molecular compatibility theory” and clinical application: a retrospective and prospective outlook. Chin J Integr Med. 2024; 30: 62–74.

    OpenUrlPubMed
20. 20.↵
    2. Gao Q,
    3. Wu H,
    4. Chen M,
    5. Gu X,
    6. Wu Q,
    7. Xie T, et al.

    Active metabolites combination therapies: towards the next paradigm for more efficient and more scientific Chinese medicine. Front Pharmacol. 2024; 15: 1392196.